Vaccinia immune globulin - DynPort Vaccine Company

Drug Profile

Vaccinia immune globulin - DynPort Vaccine Company

Alternative Names: VIGIV

Latest Information Update: 24 Jan 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DynPort Vaccine Company LLC
  • Developer DynPort Vaccine Company
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox

Highest Development Phases

  • Marketed Smallpox

Most Recent Events

  • 31 Dec 2005 Launched for Smallpox in USA (IV)
  • 22 Feb 2005 Drug "Vaccinia immune globulin - DynPort Vaccine Company" has received Orphan Drug Status for Indication "Smallpox" in USA.
  • 18 Feb 2005 Registered for Smallpox in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top